Other headlines for [ELN]

• ELN 11/18/2008 02:08pm
  Elan Corp PLC CEO: Sees 20% market share as achievable over time for Tysarbri, expects to complete pipeline transaction by mid 2009 with Oncology or other drugs- Notes could continue cost cutting measures through more...
  
• ELN 11/10/2008 01:18pm
  Elan Corp PLC Signs agreement with Azur Pharma to Develop a Once-Daily Clozapine- Clozapine is currently marketed in immediate release presentations, including Azur's proprietary orally disintegrating tablet more...
  
• JNJ 11/1/2008 06:03pm
  Johnson & Johnson Inc Study suggests treatment with Paliperidone ER improves symptoms of schizoaffective disorder-Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) more...
  
• BIIB 10/29/2008 04:29pm
  Biogen Idec, Inc. Notified of case of PML in one MS patient taking Tsyabri - filing- the patient had gotten 14 doses of Tysabri before being diagnosed with the brain illness PML
  
• ELN 10/24/2008 09:58am
  Elan Corp PLC Caris & Company Raised ELN to Average from Sell (timing uncertain)- likely pre-open
  

Healthcare sector headlines

• MAKO Today 07:46am
  MAKO Surgical Receives FDA Clearance to Market Both Its Version 2.0 Tactile Guidance System and Its Bicompartmental Knee Resurfacing Implant System- Announced it received two 510(k) clearances from the US FDA to more...
  
• UNH Today 07:40am
  UnitedHealth Group Inc Guides 2009 Commercial Enrollment down 1-1.5M y/y; Full year decline of 450-800K commercial risk based members- Sees 2009 Medicare advantage enrollemnt up 10-135K y/y - Sees 2009 Medicade more...
  
• MYL Today 07:30am
  Mylan Laboratories Inc Announces settlement agreement with Novartis related to Femara First-to-File Opportunity- Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole more...
  
• XNPT Today 07:30am
  XenoPort Inc Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease- The primary analysis comparing XP19986 to placebo did not reach more...
  
• TGEN Today 07:30am
  Targeted Genetics Corp Realigns product development priorities; Implements cost reduction measures- To focus on its ocular and neurological product candidates and its first use of expressed RNAi - Company has reduced its more...